Modulation of CYP1a2 and CYP3a6 catalytic activities by serum from rabbits with a turpentine-induced inflammatory reaction and interleukin 6

Drug Metabolism and Disposition

Volumn 34, Issue 1, 2006, Pages 27-35

  Kourylko, Oksana ^a   Fradette, Caroline ^a   Arcand, Mathieu ^a   Souich, Patrick Du ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTIOXIDANT; CYTOCHROME P450 1A2; CYTOCHROME P450 3A; CYTOCHROME P450 3A6; GENISTEIN; I KAPPA B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; PYRROLIDINE DITHIOCARBAMATE; TURPENTINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CATALYSIS; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME REGULATION; INCUBATION TIME; INFLAMMATION; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SERUM; SIGNAL TRANSDUCTION;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CATALYSIS; CELLS, CULTURED; CYTOCHROME P-450 CYP1A2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLAVONOIDS; GENISTEIN; HEPATOCYTES; IMIDAZOLES; IMMUNE SERA; INFLAMMATION; INTERLEUKIN-6; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PYRIDINES; RABBITS; SIGNAL TRANSDUCTION; TURPENTINE;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 29944433059     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.006528     Document Type: Article

References (40)

1. Adams JL, Boehm JC, Kassis S, Gorycki PD, Webb EF, Hall R, Sorenson M, Lee JC, Ayrton A, Griswold DE, et al. (1998) Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg Med Chem Lett 8:3111-3116.
2. Backes WL and Kelley RW (2003) Organization of multiple cytochrome P450s with NADPHcytochrome P450 reductase in membranes. Pharmacol Ther 98:221-233.
3. Barakat MM, El-Kadi AO, and du Souich P (2001) L-NAME prevents in vivo the inactivation but not the down-regulation of hepatic cytochrome P450 caused by an acute inflammatory reaction. Life Sci 69:1559-1571.
4. Birkenkamp KU, Tuyt LM, Lummen C, Wierenga AT, Kruijer W, and Vellenga E (2000) The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway. Br J Pharmacol 131:99-107.
5. Bleau AM, Levitchi MC, Maurice H, and du Souich P (2000) Cytochrome P450 inactivation by serum from humans with a viral infection and serum from rabbits with a turpentine-induced inflammation: the role of cytokines. Br J Pharmacol 130:1777-1784.
6. Cai H, Li Z, Davis ME, Kanner W, Harrison DG, and Dudley SC Jr (2003) Akt-dependent phosphorylation of serine 1179 and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase 1/2 cooperatively mediate activation of the endothelial nitric-oxide synthase by hydrogen peroxide. Mol Pharmacol 63:325-331.
7. Chang KC, Bell TD, Lauer BA, and Chai H (1978) Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1:1132-1133.
8. Cheng PY and Morgan ET (2001) Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2:165-183.
9. El-Kadi AO, Bleau AM, Dumont I, Maurice H, and du Souich P (2000) Role of reactive oxygen intermediates in the decrease of hepatic cytochrome P450 activity by serum of humans and rabbits with an acute inflammatory reaction. Drug Metab Dispos 28:1112-1120.
10. El-Kadi AO, Maurice H, Ong H, and du Souich P (1997) Down-regulation of the hepatic cytochrome P450 by an acute inflammatory reaction: implication of mediators in human and animal serum and in the liver. Br J Pharmacol 121:1164-1170.
11. Ferrari L, Peng N, Halpert JR, and Morgan ET (2001) Role of nitric oxide in down-regulation of CYP2B1 protein, but not RNA, in primary cultures of rat hepatocytes. Mol Pharmacol 60:209-216.
12. Flores C, Rojas S, Aguayo C, Parodi J, Mann G, Pearson JD, Casanello P, and Sobrevia L (2003) Rapid stimulation of L-arginine transport by D-glucose involves p42/44(mapk) and nitric oxide in human umbilical vein endothelium. Circ Res 92:64-72.
13. Galal A and Souich P (1999) 21-aminosteroids prevent the down-regulation of hepatic cytochrome P450 induced by hypoxia and inflammation in conscious rabbits. Br J Pharmacol 128:374-379.
14. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
15. Haas CE, Kaufman DC, Jones CE, Burstein AH, and Reiss W (2003) Cytochrome P450 3A4 activity after surgical stress. Crit Care Med 31:1338-1346.
16. Handschin C and Meyer UA (2003) Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev 55:649-673.
17. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, and Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1-20.
18. Iber H, Chen Q, Cheng PY, and Morgan ET (2000) Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-kappaB binding at the transcription start site. Arch Biochem Biophys 377:187-194.
19. Ke S, Rabson AB, Germino JF, Gallo MA, and Tian Y (2001) Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide. J Biol Chem 276:39638-39644.
20. Kent UM, Aviram M, Rosenblat M, and Hollenberg PF (2002) The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6 and 2C9. Drug Metab Dispos 30:709-715.
21. Kleinert H, Pautz A, Linker K, and Schwarz PM (2004) Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol 500:255-266.
22. Levitchi M, Fradette C, Bleau AM, Michaud D, Kourylko O, Arcand M, and du Souich P (2004) Signal transduction pathways implicated in the decrease in CYP1A1, 1A2 and 3A6 activity produced by serum from rabbits and humans with an inflammatory reaction. Biochem Pharmacol 68:573-582.
23. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
24. Meloche S (1995) Cell cycle reentry of mammalian fibroblasts is accompanied by the sustained activation of p44mapk and p42mapk isoforms in the G1 phase and their inactivation at the G1/S transition. J Cell Physiol 163:577-588.
25. Minamiyama Y, Takemura S, Imaoka S, Funae Y, Tanimoto Y, and Inoue M (1997) Irreversible inhibition of cytochrome P450 by nitric oxide. J Pharmacol Exp Ther 283:1479-1485.
26. Morgan ET, Ullrich V, Daiber A, Schmidt P, Takaya N, Shoun H, McGiff JC, Oyekan A, Hanke CJ, Campbell WB, et al. (2001) Cytochromes P450 and flavin monooxygenases-targets and sources of nitric oxide. Drug Metab Dispos 29:1366-1376.
27. Muto S, Fujita K, Yamazaki Y, and Kamataki T (2001) Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450. Mutat Res 479:197-206.
28. Nicholson TE, Dibb S, and Renton KW (2004) Nitric oxide mediates an LPS-induced depression of cytochrome P450 (CYP1A) activity in astrocytes. Brain Res 1029:148-154.
29. Nims RW, Cook JC, Krishna MC, Christodoulou D, Poore CM, Miles AM, Grisham MB, and Wink DA (1996) Colorimetric assays for nitric oxide and nitrogen oxide species formed from nitric oxide stock solutions and donor compounds. Methods Enzymol 268:93-105.
30. Parasrampuria DA, de Boer P, Desai-Krieger D, Chow AT, and Jones CR (2003) Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study. J Clin Pharmacol 43:406-413.
31. Piver B, Berthou F, Dreano Y, and Lucas D (2003) Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci 73:1199-1213.
32. Proulx M and du Souich P (1995) Inflammation-induced decrease in hepatic cytochrome P450 in conscious rabbits is accompanied by an increase in hepatic oxidative stress. Res Commun Mol Pathol Pharmacol 87:221-236.
33. Renton K (1978) Altered theophylline kinetics. Lancet ii:160-161.
34. Renton KW (2001) Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 92:147-163.
35. Riddick DS, Lee C, Bhathena A, Timsit YE, Cheng PY, Morgan ET, Prough RA, Ripp SL, Miller KK, Jahan A, et al. (2004) Transcriptional suppression of cytochrome P450 genes by endogenous and exogenous chemicals. Drug Metab Dispos 32:367-375.
36. Roberts ES, Lin H, Crowley JR, Vuletich JL, Osawa Y, and Hollenberg PF (1998) Peroxynitrite-mediated nitration of tyrosine and inactivation of the catalytic activity of cytochrome P450 2B1. Chem Res Toxicol 11:1067-1074.
37. Sonne J, Dossing M, Loft S, and Andreasen PB (1985) Antipyrine clearance in pneumonia. Clin Pharmacol Ther 37:701-704.
38. Takemura S, Minamiyama Y, Imaoka S, Funae Y, Hirohashi K, Inoue M, and Kinoshita H (1999) Hepatic cytochrome P450 is directly inactivated by nitric oxide, not by inflammatory cytokines, in the early phase of endotoxemia. J Hepatol 30:1035-1044.
39. Van Vleet TR, Mace K, and Coulombe RA Jr (2002) Comparative aflatoxin B(1) activation and cytotoxicity in human bronchial cells expressing cytochromes P450 1A2 and 3A4. Cancer Res 62:105-112.
40. Vuppugalla R and Mehvar R (2004) Hepatic disposition and effects of nitric oxide donors: rapid and concentration-dependent reduction in the cytochrome P450-mediated drug metabolism in isolated perfused rat livers. J Pharmacol Exp Ther 310:718-727.